Short Interest in Addex Therapeutics Ltd (NASDAQ:ADXN) Expands By 425.7%

Addex Therapeutics Ltd (NASDAQ:ADXN) saw a significant growth in short interest in November. As of November 15th, there was short interest totalling 18,400 shares, a growth of 425.7% from the October 31st total of 3,500 shares. Based on an average daily trading volume, of 305,400 shares, the short-interest ratio is presently 0.1 days. Approximately 2.3% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Addex Therapeutics in a report on Wednesday, October 2nd.

Addex Therapeutics Stock Down 1.8 %

ADXN stock opened at $8.62 on Friday. Addex Therapeutics has a 52-week low of $5.00 and a 52-week high of $27.90. The stock’s fifty day simple moving average is $9.79 and its 200-day simple moving average is $9.07. The stock has a market capitalization of $9.14 million, a price-to-earnings ratio of -5.26 and a beta of 1.78.

Addex Therapeutics (NASDAQ:ADXN) last posted its quarterly earnings data on Monday, September 30th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($1.70). Addex Therapeutics had a negative return on equity of 112.43% and a net margin of 850.30%. The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.26 million. As a group, analysts anticipate that Addex Therapeutics will post 9.8 earnings per share for the current fiscal year.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.